Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 12,222,000 | 12,269,000 | 11,201,000 | 12,342,000 | 11,892,000 |
| Cost of Goods | 3,435,000 | 3,372,000 | 3,033,000 | 4,812,000 | 2,957,000 |
| Gross Profit | 8,787,000 | 8,897,000 | 8,168,000 | 7,530,000 | 8,935,000 |
| Operating Expenses | 5,673,000 | 7,125,000 | 5,198,000 | 7,355,000 | 7,259,000 |
| Operating Income | 3,114,000 | 1,772,000 | 2,970,000 | 175,000 | 1,676,000 |
| Other Income | 0 | 1,000 | 1,000 | 0 | 0 |
| Pre-tax Income | 3,114,000 | 1,773,000 | 2,971,000 | 175,000 | 1,676,000 |
| Income Tax | 919,000 | 460,000 | 509,000 | 99,000 | 461,000 |
| Net Income Continuous | 2,195,000 | 1,313,000 | 2,462,000 | 76,000 | 1,215,000 |
| Minority Interests | -6,000 | 2,000 | 6,000 | 4,000 | 4,000 |
| Net Income | $2,201,000 | $1,311,000 | $2,456,000 | $72,000 | $1,211,000 |
| EPS Basic Total Ops | 1.08 | 0.64 | 1.21 | 0.05 | 0.60 |
| EPS Basic Continuous Ops | 1.08 | 0.65 | 1.21 | 0.05 | 0.60 |
| EPS Diluted Total Ops | 1.08 | 0.64 | 1.20 | 0.05 | 0.60 |
| EPS Diluted Continuous Ops | 1.08 | 0.64 | 1.21 | 0.05 | 0.60 |
| EPS Diluted Before Non-Recurring Items | 1.63 | 1.46 | 1.80 | 1.67 | 1.80 |
| EBITDA(a) | $4,125,000 | $2,783,000 | $3,982,000 | $2,055,000 | $4,268,000 |